Ignite Creation Date:
2024-05-06 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04696055
Status:
COMPLETED
Last Update Posted:
2024-05-01
First Post:
2021-01-04
Brief Title:
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1PD-L1 Immune Checkpoint Inhibitors
Sponsor:
Bayer
Organization:
Bayer